Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
The focus of this event is ‘type 1 technology’ covering aspects such as access, choice, and everyday living with type 1 technology.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > About JDRF & Our Impact > Our research > Research projects > Understanding the role of interferon in autoimmunity
Autoimmunity occurs when our immune system attacks our body’s own cells. Type 1 diabetes, multiple sclerosis and rheumatoid arthritis are all autoimmune conditions. Connect Immune Research is a collaboration between JDRF, MS Society and Versus Arthritis with support from the British Society for Immunology to tackle the underlying causes of autoimmunity. In the first Connect Immune Research project, Professor Yanick Crow at the University of Edinburgh aimed to measure interferon levels in people with different autoimmune conditions.
Interferon is a protein that affects the action of different cells of the immune system. Interferon can be harmful or beneficial in different autoimmune diseases, but we don’t yet understand why. For example, increased levels of interferon may be important in contributing to conditions like type 1 diabetes and rheumatoid arthritis. However, interferon is also used to treat people with multiple sclerosis. Researchers don’t know why interferon appears to have protective or harmful effects in different autoimmune conditions.
To better understand the relationship between interferon and autoimmunity, Yanick and his team wanted to measure the interferon levels of people living with different autoimmune conditions. Using a variety of different tests, including a new test developed by the research team, the researchers set out to measure interferon levels in individuals with lupus, rheumatoid arthritis, type 1 diabetes, Sjögren syndrome and multiple sclerosis. They aimed to find new links between interferon and these different autoimmune conditions.
Understanding why interferon is associated with different autoimmune conditions in harmful or protective ways could help improve treatments for people with autoimmune conditions, potentially by blocking the harmful effects of interferon and harnessing the good effects that it can have on the immune system.
Learning more about the relationship between interferon and autoimmunity could one day mean that doctors could better identify which treatment a person would respond to best, as well as aiding the development of drugs that regulate interferon. The researchers hope their project would also confirm whether their new test for measuring interferon is effective in different autoimmune conditions, meaning it could become the first interferon test available in routine medical practice.
Connect Immune Research is a first-of-its-kind collaboration between UK autoimmune research organisations to bring about a critical change in the way autoimmune conditions are researched. The group estimates four million people in the UK are living with an autoimmune condition, which is more than six per cent of the population. Up to a third of these people are living with more than one autoimmune condition, which can lead to more complex health needs.
“Autoimmune conditions all involve the immune system acting inappropriately, so we know they are connected. But researchers investigating different autoimmune conditions are not. Until now they have largely worked separately, focused on the specific conditions rather than the interconnected factors of autoimmunity. By bringing them together, we can find out more information about these conditions – meaning reduced costs, and more new treatments, faster. One insight into one condition could act as a skeleton key, unlocking a range of treatments and even cures.”
Lead researcher, Kourosh, says his study has the potential to transform our understanding of diabetes.
In his JDRF-funded project, Dr Richard Oram is developing a type 1 diabetes risk score to predict who will develop type 1 diabetes in the future. The research Richard and his team at the University of Exeter are doing will help how we screen people for type 1.
Professor Lucy Walker from University College London is running a research project to target a specific type of immune cell in the hope of stopping the immune attack responsible for type 1 diabetes and other autoimmune conditions.
Professor Alex Richter is a JDRF-funded researcher at the University of Birmingham who is developing an improved test to screen children for type 1 diabetes in the UK. Her new test will be more accurate and easier to use than the existing testing systems, which she hopes will encourage more people to get screened for type 1.
